Wasting is a sign of various underlying disorders and is a common feature of cancer, sepsis, and AIDS. We have developed an in vivo model to study the various stages of wasting following infection of mice with lymphocytic choriomeningitis virus cl-13. Using this model we have identified four distinct stages of wasting and have discovered that all stages occur in the different groups of mice regardless of whether the virus is cleared or persists. However, the degree and extent of wasting vary between groups of mice, depending upon the dose of virus administered. Blocking IFNγ or TNFα, which are believed to take part in the wasting process, did not affect the wasting state. Finally, we found that CD4+ T cells control the maintenance stage of wasting. We believe this model will be useful in studying the regulation of wasting during a persistent viral infection, hopefully leading to improved therapies to ameliorate the disorder.
Introduction
Individuals infected with viruses experience a loss in their quality of life. This loss may be short and transient, such as following an influenza virus infection, or may be life-long, as occurs with a persistent HIV or hepatitis infection. The host response to a virus infection is generally responsible for morbidity and mortality. Host responses to an infection that impact the quality of life include fever, malaise, and weight loss. Therefore, understanding how the host response to infection is controlled may provide needed targets to biologically reverse the wasting process, increase the quality of life, and decrease deaths related to wasting in persons infected with acute or chronic viral infections world-wide.
Wasting is a syndrome associated with many diseases (Delano and Moldawer, 2006; Doehner and Anker, 2002; Inagaki et al., 1974; Tisdale, 2002) such as cancer, congestive heart failure, chronic obstructive pulmonary disease, HIV, and tuberculosis (TB). The components of wasting include weight loss, anorexia, depletion of both fat and protein masses, muscle atrophy, gain in the proportion of body water, and a variety of metabolic changes Norton et al., 1987) . Indirect evidence for the role of cytokines has been derived from studies in which chronic administration of cytokines mimics wasting Tracey et al., 1988) . More specifically, evidence that TNFα has a role in wasting come from experiments in which the wasting syndrome associated with infections or with tumors is attenuated by treatment with antibodies to neutralize TNFα (Costelli et al., 1993; Gelin et al., 1991; Sherry et al., 1989; Truyens et al., 1995; Yoneda et al., 1991) . However, in many of these studies the administration of anti-TNFα antibodies not only reduces wasting, but also either reduced tumor size or parasitemia. Therefore, it is difficult to determine what the biological effect of anti-TNFα treatment is in these studies.
Additional cytokines have been implicated in wasting. IL-1 has been shown to induce wasting in rats, similar to TNFα and LPS . While IL-6 has been shown to suppress the development of wasting associated with tumor growth (Strassmann et al., 1992) . TNFα, IL-1, and IL-6 are triggers of the acute phase response that is implicated in many diseases (Hirano, 1994) . It is the prevailing hypothesis that wasting develops as a result of chronic overstimulation induced by several cytokines acting in concert and affecting many different cells and organ systems. However, antagonism of one or all of these cytokines has not proven clinically beneficial in reversing the wasting state (Delano and Moldawer, 2006) . Therefore, investigations into the mechanisms responsible for the development of wasting are needed. Virology 425 (2012) [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] LCMV cl-13 is an established model of a persistent virus infection (reviews; (Asano and Ahmed, 1995; Oldstone, 2002 Oldstone, , 2006 Oldstone et al., 1985; Yi et al., 2010) ). The LCMV model has led to the development of experimental therapies to treat persistent infections (Finnefrock et al., 2009; Larrubia et al., 2009) and towards understanding of the differences between acute and persistent viral infections (Wherry et al., 2003) . LCMV has been used to study virus induced wasting (Doherty et al., 1993; Kamperschroer and Quinn, 2002; Zajac et al., 1996; Zhou et al., 2009) . From these LCMV wasting studies it was found that TNFα does not play a role (Kamperschroer and Quinn, 2002) in the virus induced wasting, and that CD4+ T cells were important in the wasting process when CD8+ T cells were not present or the virus was injected intracranial (Doherty et al., 1993; Fung-Leung et al., 1991; Zajac et al., 1996; Zhou et al., 2009) . Though CD4+ T cells have been shown to be important in LCMV induced wasting, their role in the process is poorly understood.
Much of our knowledge about the mechanism of wasting is indirect, detecting serum levels of cytokines or forcing cachexia by continuous administration of a variety of cytokines or stimulants such as LPS. Therefore, in vivo models of wasting in natural infections are needed. We have used the LCMV model as a tool to study the infection-induced wasting state in vivo. This model has the potential to be valuable in dissecting the mechanism of this clinically important, debilitating process. We have found that wasting occurs in four distinct phases: 1) initiation, 2) decline, 3) recovery, and 4) maintenance. Our data suggest that each stage is independently regulated and that specific therapies to target each stage may be possible. Specifically, our data expand on the role that CD4+ T cells play during the wasting syndrome.
Results

An intermediate dose of cl-13 leads to enhanced morbidity
We investigated the effect of 5-fold differences in the infectious dose on morbidity after cl-13 infection. We made five-fold dilutions of cl-13, using a very high (1× 10 7 pfu), high (2× 10 6 pfu), intermediate (4× 10   5 pfu), and low (8× 10 4 pfu) dose of virus to infect C57BL/6 mice intravenously. Mice infected with different doses of cl-13 had strikingly different patterns of morbidity (Fig. 1a) . All animals lost a small amount of body weight during the first 2 days of infection, and then recovered. They then underwent a second round of body weight loss beginning 6 days post infection. Differences in morbidity between the groups were observed by 8 days post-infection. In this second wave of weight loss, mice infected with a low dose of cl-13 lost significantly less body weight than all other groups of mice, and regained this body weight by day 10 post infection ( Fig. 1a , p = 0.001 two-way ANOVA). Mice infected with high (2× 10 6 ) or very high (1× 10 7 ) doses of virus experienced wasting typical of cl-13 infected mice, losing about 20% of their body weight by day 8 post-infection. To our surprise, mice infected with the intermediate dose of cl-13 experienced enhanced wasting and prolonged morbidity relative to the higher and lower virally infected groups (Fig. 1a, open circles) .
Differences in the clinical outcome were also apparent in illness scores. Animals infected with the intermediate dose of virus showed high illness scores until about 16 days post-infection as compared to animals given the higher doses (Fig. 1b) . Intriguingly, animals given the low dose of cl-13 did not experience apparent illness beyond their moderate weight loss (Fig. 1b) , though the initial infectious dose was only five-fold lower than the dose causing the greatest illness. Mice infected with the rapidly cleared LCMV Armstrong strain at 2 × 10 6 pfu i.v., had a similar disease course as compared to the low dose LCMV cl-13 infection (data not shown).
Having observed this dose-dependent pattern of morbidity and illness in LCMV cl-13 infected mice we investigated whether variation in disease was due simply to corresponding changes in viral load. Mice were bled weekly and titers in the plasma were determined by plaque assay. At 1 week post-infection almost all mice infected with the low dose of virus had undetectable plasma viremia (Fig. 1c) , similar to what is seen using the less pathogenic Armstrong strain of LCMV, (Wherry et al., 2003) and from our own experiments with Armstrong (data not shown). Mice infected with intermediate, high and very high doses of virus had similar titers of LCMV in their plasma at weeks 1, 2 and 3 post-infection (Fig. 1c) . Mice infected with low dose cl-13 were able to control virus in all infected tissues between 15 and 22 days post infection (data not shown) whereas mice infected will all other doses of the same virus inoculum had virus titers measurable in the kidney (Fig. 1d ) and brain (data not shown) out to day 60 post infection. Thus, differences in viral titers by the first week of infection did not explain the differences in wasting observed in the medium, normal, and high dose groups at this time.
Viral titers are controlled very early in low dose-infected mice but do not fully explain differences in morbidity
We reasoned that events occurring early following infection may determine the morbidity differences that emerged at day 8 postinfection. Therefore, we closely examined the relationship between virus dose and very early kinetics of tissue viral loads. By day 5 post infection, there were no significant differences in viral titers measured between all groups of cl-13 infected mice (data not shown). By day 6 in the liver, the low dose infected mice had significantly lower levels of virus that continued through day 8 of the infection (Fig. 2) . This pattern was also true in the brain but not the kidney (Fig. 2) . On day 8 post infection, the low dose group viral titers in the kidney were not significantly different than the other infected groups of mice. Mice infected with the intermediate and high doses of virus had increasing levels of virus in the brain on days 7 and 8 post infection, while low dose mice rapidly established control of viral replication in the brain.
Overall, mice infected with the low dose of cl-13 had significantly reduced viral titers in all tissues tested, indicating that a systemic infection was transiently established and then rapidly cleared. Also of interest, the intermediate dose groups' viral titers in tissues were similar to or lower than the high dose group at these early time points. By day 15, cl-13 was cleared from the low dose infected mice and there was no significant difference between the intermediate and high dose infected animals (data not shown). Thus, the prolonged morbidity and illness observed in the intermediate dose group as compared to the high dose group cannot be explained by greater amounts of virus replicating in their tissues.
Differences type I IFN production and CD69 expression on CD4+ and CD8+ T cells
We next hypothesized that immunological events within the first week of infection determined the course of disease. Since clearance of LCMV requires CD8+ T cells (Moskophidis et al., 1987) , we examined T cell responses over time in the blood. All groups experienced a post-infection in the liver (a), kidney (b) and brain (c) titers. All statistics were done using the student's t-test. Data pooled from 2 independent experiment n = 3-5 mice/group/ experiment, error bars represent mean.
similar drop in total CD8+ T cells in the blood during the first 3 days after infection (data not shown). Other groups have attributed this early attrition of T cells to type I interferon (IFN-I) (Bahl et al., 2006) . Mice infected with the low dose cl-13 had a significantly lower IFN-I response in the plasma compared to those infected with higher doses of cl-13 ( Fig. 3a , one way ANOVA p = 0.006). Type I IFN levels waned over time and are undetectable in all groups on days 5-8 post-infection (data not shown). The significantly reduced levels of type I IFN in the low dose infected group of mice correlated with their reduced levels of CD69 expression on both CD4+ and CD8+ T cells . CD69 is upregulated non-specifically on T cells following an LCMV infection, probably in response to IFN-I (Shiow et al., 2006) .
Mice infected with low dose cl-13 have more peripheral total CD8+ and CD4+ T cells and altered patterns of PD-1 expression
By day 8 post-infection, the low dose group had significantly elevated numbers of CD8+ cells (Fig. 4a , p = 0.0001 one way ANOVA), LCMVspecific GP33-tetramer positive cells (Fig. 4b , p = 0.0001, one-way ANOVA) and CD4+ T cells in the blood (Fig. 4c , p = 0.0001, one-way ANOVA). CD8+ T cell counts in the other groups of LCMV-infected mice rebounded to normal levels by day 8, but were not significantly different from each other. Therefore, mice infected with 8 × 10 4 pfu of cl-13 had increases in both CD4+ T cells and CD8+ T cells while all other groups showed equivalent (or lower) CD4+ T cell and CD8+ T cell counts in the blood. This increase in absolute counts in low-dose infected mice appeared to be due to expansion of LCMV-specific cells. Following activation, antigen specific T cells upregulated PD-1 (Barber et al., 2006) . Interestingly, we noticed that mice infected with the low dose of cl-13 had differences in PD-1 expression on CD8+ and CD4+ T cells. PD-1 was expressed on the CD4+ T cell effector population (CD44 + CD62L
Lo ) in mice infected with the low dose of virus at 1 and 2 weeks post infection and then significantly down regulated by 3 weeks post infection ( Fig. 4d and e, p = 0.0001 one way ANOVA). On CD8+ T cells we observed a different pattern of PD-1 expression: by day 8 post-infection, CD8+ T cells from mice given the low dose of cl-13 had significantly lower levels of PD-1 expression than CD8+ T cells from mice infected with the higher doses of virus (Figs. 4f and g, p = 0.001 one way ANOVA). The difference in PD-1 MFI appeared to be due to lower levels of PD-1 expressed on LCMV-specific CD8+ T cells, as revealed by staining with a GP33-specific tetramer (Figs. 4h and i, p = 0.0001 one way ANOVA). Virus is still present in the organs of the low dose-infected mice at this time (Fig. 2) , so these data indicate that PD-1 down regulation on CD8+ T cells does not strictly correlate with clearance of the viral antigen (Sharpe et al., 2007) . With respect to the high and very high dose groups (2 × 10 6 and 1 × 10 7 pfu), PD-1 expression was not significantly altered between weeks 1-3 post infection. We did detect a significant difference in the level of PD-1 expression on CD4+ T cells that were CD44 . 4f and g, p = 0.0004 and 0.0003 respectively, one way ANOVA). These data show that an increased frequency of activated, PD-1 expressing T cells was correlated with prolonged morbidity when present in conjunction with high levels of virus (Fig. 1a ).
An early CD4+ T cell response is followed by a significant expansion of the CD8+ T compartment in mice infected with the low dose of cl-13
Since differences between the peripheral T cell responses in the various groups of mice were evident by day 8 post-infection (Figs. 4d-i) , we decided to focus on early antigen-specific T cell responses. Mice were infected with low, intermediate, and high doses of cl-13 and sacrificed on days 6, 7, and 8 post-infection. These time points correspond divergence of different groups of mice in the extent of their weight loss. Functionality of antigen-specific splenic T cells was examined. At day 6 post-infection, both CD4+ and CD8+ T cell responses to immunodominant epitopes were readily detectable (Figs. 5a, c-d ). On day 6 post-infection, mice infected with the low dose made significantly larger CD4+ T cell responses to the GP61 epitope than those made by mice that received the intermediate and high doses of virus (Figs. 5a and b , p = 0.01 one-way ANOVA). The difference in magnitude of CD4+ T cell responses between low dose mice and the intermediate or high dose mice continued through day 8 post infection ( Fig. 5a ). At that time the low dose-infected mice had GP61-specific responses, which were 3 to 5-fold larger in frequency than responses made by mice that received higher doses of virus (Fig. 5b , day 7 p = 0.0043 and day 8 p = 0.04, one-way ANOVA).
In the CD8+ T cell compartment, all groups of mice made responses against GP33 and NP396 of comparable frequency at day 6 postinfection, as measured by IFNγ/TNFα secretion in response to peptide (Figs. 5c and d) . However, the np396 response was significantly elevated in mice infected with low dose cl-13 as compared to mice infected with the very high dose. By days 7 and 8 post-infection though, the difference in the magnitude of the CD8+ T cell responses made by the low dose group and the other groups was dramatic (Figs. 5e and f, day 7 gp33 p = 0.0001, np396 p = 0.001 and day 8 gp33 p = 0.03 and np396 p = 0.01, one-way ANOVA). The low dose cl-13 infected mice made 2 to 10 fold higher frequency responses compared to intermediate and high dose groups. The magnitude of responses made by the intermediate and high dose groups was similar to each other.
In summary, mice infected with a low dose of cl-13 (8 × 10 4 pfu) had a higher frequency of CD4+ T cells 6 days post-infection as compared to mice infected with the intermediate or high doses. This divergence in CD4+ T cell response magnitude was followed by a divergence in the magnitude of CD8+ T cell responses on days 7 and 8 post infection (Figs. 5b, e and f). These results indicate that the expansion phase of T cell responses against LCMV was affected by the initial dose of virus given, with a lower initial dose resulting in significantly larger T cell responses. This robust response occurred at the same time viremia was being cleared in these animals and these mice experienced the least severe wasting (Fig. 1a) .
Measurement of pyrogens in plasma
The rapid clearance of virus observed in mice infected with the low dose of cl-13 was associated with reduced morbidity (Fig. 1a) . However, neither quantitation of early T cell responses nor of viral loads satisfactorily explained the enhanced morbidity experienced by the mice infected with an intermediate dose (4× 10 5 pfu) as compared to mice that received higher doses of cl-13. This led us to quantitate the levels of plasma cytokines that have been previously implicated in immunopathology (Kamperschroer and Quinn, 2002) and referred to as pyrogens. Pyrogens are substances that induce a fever response. Wellcharacterized pyrogens include TNFα and IL-1β (Stefferl et al., 1996) . We performed a Luminex assay to determine whether we could detect differences in cytokine levels known to be important in morbidity and wasting. From each dose group, we randomly tested six mice from two independent experiments for cytokine measurement and observed no differences in IL-6, IL-10, or IL-1β levels between the groups (data not shown). There was a peak of IFNγ production at day 6 post infection that was reduced at least five-fold by day 7 post infection in all groups of infected mice (Fig. 6a) . Interestingly, mice infected with 2 × 10 6 pfu had a significant reduction in circulating levels of IFNγ at day 6 as compared to the low dose infected mice (Fig. 6a) . We also detected increased levels of TNFα 6 days post infection in all infected groups (Fig. 6b ). In the low dose-infected group, this TNFα peak was reduced by day 7 and was undetectable by day 8. In contrast, TNFα levels were detectable in the plasma of mice infected with the normal or medium doses of cl-13 out to 15 days post infection (Fig. 6b) . These data suggested that IFNγ and TNFα levels might have a role in the increased morbidity experienced by the mice infected with an intermediate dose of cl-13. We reasoned that blocking TNFα or IFNγ might thus ameliorate the prolonged morbidity. To test this hypothesis, mice were infected with 4 × 10 5 pfu of cl-13 and treated on days 5
and 7 with either IFNγ or TNFα neutralizing antibodies. Treatment had no effect on morbidity (Fig. 6c ) or viral titers (Figs. 6d and e). Our results confirm previous studies using anti-TNFα antibodies during an LCMV infection (Kamperschroer and Quinn, 2002) . Our lab has also used the IFNγ blocking antibody to successfully reverse the antiviral state following an in vivo cl-13 infection (unpublished data). Therefore, we believe that both blocking antibodies were used at a biologically relevant dose. Although levels of IFNγ and TNFα were elevated following infection with the different doses of cl-13, blocking these pyrogens individually was not sufficient to ameliorate morbidity. Therefore, IFNγ and TNFα have a role in inflammation, they do not individually influence wasting in our model.
CD4+ T cells maintain the wasting disease following the intermediate dose of cl-13
CD4+ T cells are known to play a role in morbidity following an LCMV infection (Doherty et al., 1993; Fung-Leung et al., 1991; Zajac et al., 1996; Zhou et al., 2009 ). Therefore we wanted to investigate if CD4+ T cells were impacting wasting in our model. Since the wasting state initiates between days 5-6 in all groups, we tested whether depleting CD4+ T cells on day 5 following infection with the different doses of cl-13 would perturb morbidity. Depleting CD4+ T cells was effective following GK1.5 antibody administration 5 days post cl-13 infection (data not shown). Following depletion, CD4+ T cells reappear in the circulation within 1 week (data not shown). CD4+ T cell depletion did not affect the initiation of wasting state following cl-13 infection (Figs. 7a-c) . However, 5 days after depletion of CD4+ T cells the mice began to recover more rapidly than untreated infected controls (Figs. 7a-c) . By 11 days post infection mice depleted of CD4+ T cells have a significant increase in the body weight (Fig. 7d) . The recovery of body weight was independent of virus loads because treated mice had the same levels of virus as untreated mice (Figs. 7e and f) . Clearance of the virus in the low dose infected group was not altered in CD4 depleted animals (data not shown). In addition CD8+ T cell responses were not altered when CD4+ T cells were depleted at this time (Fig. 7g) . These data suggest that the presence of CD4+ T cells is not required to initiate wasting, but CD4+ T cells are required to maintain the morbid state.
Discussion
Wasting is a debilitating, difficult to treat condition that is an essential part of the pathology of many diseases. Here we describe an All statistics were done using the student's t-test. e-f. LCMV titers in tissues were measured 3 weeks after infection with e. Intermediate and f. high dose of LCMV cl-13. d. Representative plot of splenocytes that were stimulated with LCMV gp33 peptide and IFNγ production was measured. Number indicates % of CD8+ Thy1.2+ cells making IFNγ. All error bars indicate mean + SD. Data from two independent experiments are displayed.
in vivo model for dissecting the distinct stages of the wasting process ( Fig. 1 ). In our model, infection with different doses of the same virus leads to marked differences in the severity of morbidity. These differences were not explained completely by either differences in the levels of viremia or by the immune responses engendered, but appeared to be a result of the interaction of these two variables. We have found and confirmed that TNFα (Kamperschroer and Quinn, 2002) is not sufficient to drive wasting, despite its presence during cachexia. The initial interactions of the pathogen and the host are critical. Our model demonstrates that the initial virus dose has an important role in determining the outcome of disease. We describe a system in which a potentially persistent viral infection is either cleared by the host without causing discernable illness, or establishes a persistent infection characterized by significant wasting and immune exhaustion. Diseases such as hepatitis C (HCV) (Lewis-Ximenez et al., 2010) , and hepatitis B (HBV) (Webster and Bertoletti, 2002) have similar diverse outcomes in humans. Once an infection has been established, it is difficult to determine whether immunological responses correlated with particular outcomes are causes or consequences of the persistent infection. Our model supports wasting as a common biological process regardless of whether the virus is cleared or persists. (Fig. 1a) . It has been well established that T cells contribute to the pathology of LCMV infection. Therefore, we investigated whether differences in T cell responses could account for differences in wasting. PD-1 levels on CD4+ T cells 8 days following infection and PD-1 levels on CD8+ T cells 15 days post infection are significantly increased in mice infected with the intermediate dose of cl-13 as compared to all other groups of infected mice, (Figs. 4d and f respectively) indicating greater T cell activation. Two weeks following infection, a time when PD-1 levels remain elevated in the intermediate dose group, the mice begin to recover from wasting. When CD4+ T cell PD-1 levels are significantly increased in the intermediate dose group 8 days post infection, mice are maintaining their morbid state. Therefore, altered CD4+ T cell activation 1 week post infection in the intermediate dose group may drive the enhanced wasting.
CD4+ T cells have also been implicated in wasting, but their exact role is unknown (Doherty et al., 1993; Fung-Leung et al., 1991; Zajac et al., 1996; Zhou et al., 2009 ). Some of these published studies suggest that CD4+ T cells have a role in wasting when CD8+ T cells are also depleted. These results demonstrate that without both CD4+ T cells and CD8+ T cells wasting does not occur. Using our model we found that depletion of CD4+ T cells led to a more rapid recovery from wasting in all mice infected with cl-13 regardless of dose, (Figs. 7a-d ) and independent of virus load (Figs. 7e-f) . Although, mice infected with the intermediate dose of cl-13 and depleted of their CD4+ T cells had the most significant difference in morbidity (Fig. 7b) , these mice do not normally recover from morbidity until 3 weeks following infection (Fig. 1a) . The low and high dose infected mice naturally have a period of recover (Fig. 1a) and CD4+ T cell depletion accelerates this recovery period (Figs. 7a and c) . This suggests that CD4+ T cells contribute to the maintenance of wasting and further prevent mice infected with the intermediate dose of virus from entering a recovery period. It is important to point out that while there do not appear any obvious differences in the CD4+ T cell response following the intermediate and high doses of cl-13, the intermediate has a prolonged morbid state that CD4 depletion partially reverts. Therefore, other to be determined factors may also contribute in maintaining the morbid state. We are currently investigating whether the CD4+ T cell response transitions from an early effector to a regulatory response during the maintenance stage of wasting (Fahey et al., 2011) . Additionally, we have depleted CD8+ T cells in the low dose infected mice at 5 days following infection. CD8+ T cell depletion exasperated the morbid state (data not shown) and therefore was not attempted in the higher dose groups. Other cells such as antigen presenting cells may play a role in this complex process.
TNFα, also known as cachectin, is known to cause a lethal state of shock and a chronic wasting syndrome when produced in abundance (Araki et al., 2009; Beutler and Cerami, 1988) . Pro-inflammatory cytokines play a role in LCMV wasting disease when the virus is administered by intracranial inoculation (Kamperschroer and Quinn, 2002) . In the present study we found that both IFNγ and TNFα were elevated during the wasting state (Figs. 6a-b) . However, we did not find an obvious relationship between TNFα or IFNγ and the enhanced morbidity and wasting in mice infected with the intermediate cl-13 dose of 4 × 10 5 pfu (Figs. 6c-e). Thus it is possible that the presence of these inflammatory cytokines during virus induced wasting may be correlative but not causative. Using our model of LCMV cl-13 infection we propose that wasting occurs in 4 distinct stages: initiation, decline, recovery, and maintenance (Fig. 8) . Depending on the dose of the original inoculum, the time that each group enters a particular stage, or transitions to the next stage, is different. We did not find that increased viral titers necessarily corresponded to increased wasting. Nor did we find that mice that had a very strong T cell response experienced more wasting. Rather, the interaction of these two parameters may underlie the illness observed. Using this model, in which the same virus causes different degrees of pathology, we hope to further elucidate how the different stages of wasting are regulated in the context of a viral infection. This knowledge may then prove useful in developing interventions to ameliorate the symptoms associated with many diseases.
Materials and methods
Mice and virus
Female wild type C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA) and used at 6-8 weeks of age. All mice were maintained under specific pathogen-free conditions at the UCSF SFGH animal facility and were used in accordance with university animal welfare guidelines. LCMV cl-13 and Armstrong were a gift from Dr. Mehrdad Matloubian and were propagated on BHK cells. Age-and sex-matched animals were given 5-fold dilutions of cl-13 virus made in serum-free RPMI (8 × 10 1 × 10 7 pfu) by tail-vein injection. LCMV Armstrong was used at a dose of 8 × 10 4 or 2 × 10 6 pfu. Following infection, mice were weighed daily for the first month then weekly thereafter. Body weight was calculated as a fraction of a mouse's starting body weight. Mice were scored for illness by giving a point for each of the following conditions: ruffled fur, weight loss exceeding 15%, visually lethargic, lethargic to the touch, and a hunched back. Mice were euthanized according to an approved IACUC protocol. Titers of virus were determined by plaque assay on Vero cells as previously described (Ahmed et al., 1984) .
Type I IFN bioassay
Type I interferon bioassay was used to measure IFN-I as described (Cembrzynska-Nowak, 1989) . The murine IFN standard (Biomedical Laboratories PBL, 12100-1) at a final concentration of 100 U ml −1 was used as a control.
Sample collection, cell suspension and flow cytometry Heparinized blood was collected by tail vein nick. The blood was spun down at 12,000 rpm and the plasma collected for plaque and cytokine assays. Blood cells were then resuspended and stained for 15 min at room temperature with fluorochrome-conjugated antibodies. Fluorochrome-conjugated antibodies were obtained from BD Pharmingen (San Diego, CA), and eBiosciences (San Diego, CA). Red blood cells were lysed using BD FACS Lysing Solution (BD Biosciences, Franklin Lakes, NJ); cells were washed twice in FACS Buffer (PBS/ 1%BSA), and fixed (PBS/1% PFA) prior to running on a flow cytometer. Single cell suspensions of splenocytes were prepared by mashing the spleen through a 70 μm cell were lysed using ACK Buffer (SigmaAldrich, St Louis, MO) and washed with RPMI. For intracellular cytokine staining assays, splenocytes were resuspended in RPMI supplemented with 10% FCS (Hyclone) and stimulated with 2.5 μM peptide for 6 h at 37°C in the presence of GolgiPlug (BD Biosciences). Cells were stained for surface and intracellular markers using the BD Cytofix/Cytoperm Kit following manufacturer's protocol. Tetramers (GP33) were by synthesized by the Microchemical Facility Core (Emory University, Atlanta, GA). Samples were read on an LSRII flow cytometer (BD Biosciences) and results were analyzed using FlowJo software (TreeStar, Ashland, OR).
Peptides
Peptides gp33-41 (KAVYNFATM), np366-374 (ASNENMDAM), and gp61-80 (GLNGPDIYKGVYQFKSVEFD), were synthesized by Anaspec (Fremont, CA).
In vivo antibody treatment CD4+ T cell depletion was done using the antibody clones GK1.5 at 500 μg/mouse/dose administered at the indicated time points i.p. Anti-IFNγ antibodies were administered at 200 μg/mouse/dose at indicated time points i.p. Anti-TNFα antibodies were administered at 100 μg/mouse at the indicated time points. GK1.5, and anti-IFNγ antibodies were provided by the UCSF hybridoma core facility. Anti-TNFα antibodies were purchased from MyBioSource, (MBS670094, Rat Anti-Mouse TNF-a-LE/AF).
Luminex analysis
For Luminex assays, plasma was thawed at room temperature, gently vortexed, then centrifuged at 13,200 rpm for 10 min at 4°C immediately prior to testing. Cytokines were measured using a MILLI-PLEX MAP High Sensitivity Mouse Cytokine Panel (7-plex, Millipore) according to the manufacturer's instructions. Plates were read on a Luminex-100 (Millipore) with Masterplex QT software (MiraiBio).
Statistical analysis
Statistical significance was determined by Standard two tailed Ttest or 1 or 2-way ANOVA, using Prism 5 (Graphpad Software, La Jolla, CA).
